Savara Inc (SVRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Savara Inc (SVRA) has a cash flow conversion efficiency ratio of -0.123x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.06 Million) by net assets ($203.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Savara Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Savara Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Savara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Savara Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savara Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Er Kang Pharmaceutical
SHE:300267
|
0.040x |
|
Dorian LPG Ltd
NYSE:LPG
|
0.044x |
|
GoGold Resources Inc.
TO:GGD
|
0.044x |
|
Verusa Holding AS
IS:VERUS
|
-0.014x |
|
Priortech
TA:PRTC
|
0.000x |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
-0.020x |
|
Hyosung TNC Corp
KO:298020
|
0.049x |
|
East China Engineering Science and Technology Co Ltd
SHE:002140
|
0.084x |
Annual Cash Flow Conversion Efficiency for Savara Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Savara Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Savara Inc (SVRA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $203.13 Million | $-101.04 Million | -0.497x | +4.28% |
| 2024-12-31 | $171.45 Million | $-89.09 Million | -0.520x | -42.85% |
| 2023-12-31 | $140.37 Million | $-51.06 Million | -0.364x | -13.46% |
| 2022-12-31 | $107.78 Million | $-34.55 Million | -0.321x | -15.58% |
| 2021-12-31 | $144.50 Million | $-40.08 Million | -0.277x | +55.17% |
| 2020-12-31 | $64.38 Million | $-39.84 Million | -0.619x | -39.45% |
| 2019-12-31 | $101.70 Million | $-45.12 Million | -0.444x | -- |
| 2018-12-31 | $0.00 | $-39.27 Million | x | -- |
| 2017-12-31 | $119.31 Million | $-28.23 Million | -0.237x | -201.43% |
| 2016-12-31 | $-35.88 Million | $-8.37 Million | 0.233x | +116.92% |
| 2015-12-31 | $23.89 Million | $-32.95 Million | -1.379x | -228.28% |
| 2014-12-31 | $58.66 Million | $-24.64 Million | -0.420x | -12.91% |
| 2013-12-31 | $47.81 Million | $-17.79 Million | -0.372x | -11.72% |
| 2012-12-31 | $41.79 Million | $-13.92 Million | -0.333x | -40.42% |
| 2011-12-31 | $56.78 Million | $-13.47 Million | -0.237x | +24.12% |
| 2010-12-31 | $26.69 Million | $-8.34 Million | -0.313x | +83.47% |
| 2009-12-31 | $6.67 Million | $-12.62 Million | -1.891x | +52.35% |
| 2008-12-31 | $6.00 Million | $-23.79 Million | -3.968x | -526.87% |
| 2007-12-31 | $31.03 Million | $-19.64 Million | -0.633x | +19.92% |
| 2006-12-31 | $19.96 Million | $-15.77 Million | -0.790x | -153.12% |
| 2005-12-31 | $-7.83 Million | $-11.65 Million | 1.488x | +456.18% |
| 2004-12-31 | $12.39 Million | $-5.18 Million | -0.418x | +23.41% |
| 2003-12-31 | $4.12 Million | $-2.25 Million | -0.545x | -142.20% |
| 2002-12-31 | $-852.73K | $-1.10 Million | 1.292x | -51.78% |
| 2001-12-31 | $-638.49K | $-1.71 Million | 2.680x | +1922.59% |
| 2000-12-31 | $14.61 Million | $-2.15 Million | -0.147x | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne,… Read more